Clarity Pharmaceuticals Ltd (CU6 AU): An Attractive Bet on Red Hot Radiopharmaceutical Field
Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a...
349 Views
Clarity Pharmaceuticals (CU6) - O/W: Better Late than Fuzzy
Evaluation of Clarity’s opportunity with their 64Cu-SARbisPSMA PET/CT agent in prostate cancer drives our upgrade in part – recognising that they...
298 Views
Clarity Pharmaceuticals (CU6) - Cash for Copper
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh). Clarity have recently...
419 Views
Clarity Pharmaceuticals (CU6) - More SECuRE than Ever
Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC)...
344 Views
Clarity Pharmaceuticals (CU6) - More Positive Data SECuREd
Clarity have announced further positive data from their ongoing Phase I/IIa theranostic trial in mCRPC with 64Cu-/67Cu-SAR-bisPSMA.
334 Views